Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancer.

MLA

Mahon, Kate L., et al. “Clinical Validation of Circulating GDF15/MIC-1 as a Marker of Response to Docetaxel and Survival in Men with Metastatic Castration-Resistant Prostate Cancer.” The Prostate, vol. 84, no. 8, June 2024, pp. 747–55. EBSCOhost, https://doi.org/10.1002/pros.24691.

APA

Mahon, K. L., Sutherland, S. I., Lin, H. M., Stockler, M. R., Gurney, H., Mallesara, G., Briscoe, K., Marx, G., Higano, C. S., de Bono, J. S., Chi, K. N., Clark, G., Breit, S. N., Brown, D. A., & Horvath, L. G. (2024). Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancer. The Prostate, 84(8), 747–755. https://doi.org/10.1002/pros.24691

Chicago

Mahon, Kate L, Sarah Im Sutherland, Hui Ming Lin, Martin R Stockler, Howard Gurney, Girish Mallesara, Karen Briscoe, et al. 2024. “Clinical Validation of Circulating GDF15/MIC-1 as a Marker of Response to Docetaxel and Survival in Men with Metastatic Castration-Resistant Prostate Cancer.” The Prostate 84 (8): 747–55. doi:10.1002/pros.24691.